Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer

Table 3 Effects of drug interactions between components of different combinations

Modalities	Cell Line	Combination Index (CI¹)	Drug Alone (×IC₅₀)			Dose Reduction Index (×IC₅₀)			R³	Effect⁴
		IC² ₅₀	PNP	Doc	Car	PNP	Doc	Car
Docetaxel Carboplatin	SKOV⁵	0.96	-	5.01	1.34	-	2.7	1.68	0.98	Additive +
	OVCAR⁶	0.89	-	2.76	2.16	-	2.1	2.44	0.99	Additive +
PNP-GDEPT Docetaxel	SKOV	0.43	8.22	5.01	-	6.12	3.7	-	0.98	Synergy +++
	OVCAR	0.21	2.03	2.76	-	7.97	10.82	-	0.93	Strong Synergy ++++
PNP-GDEPT Carboplatin	SKOV	0.29	8.22	-	1.34	12.36	-	4.7	0.97	Strong Synergy ++++
	OVCAR	0.28	2.03	-	2.16	5.66	-	9.08	0.96	Strong Synergy ++++
GDEPT Docetaxel Carboplatin	SKOV	0.37	8.22	5.01	1.34	13.96	8.51	5.3	0.96	Strong Synergy ++++
	OVCAR	0.11	2.03	2.76	2.16	19.89	27.02	31.9	0.94	Very Strong Synergy +++++

¹ Combination index values generated when drugs were combined at constant ratio of 1:1 e.g. IC₂₅ of docetaxel with IC₂₅ of carboplatin; ²ED, Effective dose, which can result in 50, 75 and 90% of cell killing; ³The linear correlation coefficient, R, of the median-effect plot. The acceptable range of 'R' values varies with the type of system used; Enzyme or receptor systems (r > 0.96), tissue culture systems (r > 0.90) and animal experiments (r > 0.85); ⁴Combination effects, CI value 0.90-1.10 signifies additivity (+); CI 0.7-0.85 moderate synergism (++); CI 0.85-0.9 slight synergies (+++); CI 0.30-0.70 synergism (++++); CI 0.10-0.30 strong synergism (+++++) and CI 0.01-010 very strong synergism (++++++); ⁵ represents SKOV-3; ⁶ represents OVCAR-3

ISSN: 1471-2407